@article{oai:repo.qst.go.jp:00047700,
 author = {Jin, Zhao-Hui and Furukawa, Takako and Ohya, Tomoyuki and Degardin, Mélissa and Sugyo, Aya and B, Tsuji Atsushi and Fujibayashi, Yasuhisa and Zhang, Ming-Rong and Higashi, Tatsuya and Boturyn, Didier and Dumy, Pascal and Saga, Tsuneo and 金 朝暉 and 古川 高子 and 大矢 智幸 and 須尭 綾 and 辻 厚至 and 藤林 康久 and 張 明栄 and 東 達也 and 佐賀 恒夫},
 issue = {4},
 journal = {Nuclear medicine communications},
 month = {Mar},
 note = {Copper-67 (Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated for developing innovative approaches for the large-scale production of Cu. Encouraged by these, we performed Cu-radiolabeling of a tetrameric cyclic Arg-Gly-Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), the transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis. We also evaluated the therapeutic potential and safety of this radiocompound.},
 pages = {347--355},
 title = {67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.},
 volume = {38},
 year = {2017}
}